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a r t I C l e S During development, neurons of the CNS acquire distinct molecular, anatomical and physiological properties. Development of these traits is dictated by pan-neuronal and lineage-specific molecular cues, which in combination define neuronal subtype-specific identity and set the basis for neuronal diversity.
Among other regions of the mammalian CNS, the cerebral cortex stands as a prime example of how expanded neuronal diversity served the evolution of complex behavior. Here an extraordinary number of neuronal subtypes integrate into local and long-distance circuitry subserving sensory, motor and high-level cognitive functions 1 . The majority of cortical neurons are excitatory projection neurons. Their classification is largely based on axonal projection targets, but it is clear that multiple traits-molecular identity, primary and collateral axonal connections, somatodendritic morphology and electrophysiological activity-must be taken into account to accurately distinguish individual projection neuron subtypes 2 . The molecular regulatory logic that orchestrates acquisition of multiple class-specific features is not understood for any neuronal subtype of the cerebral cortex.
CSMN are one specialized class of cortical excitatory neurons, which connect layer Vb of the cortex to the spinal cord. At the molecular level, CSMN are the most extensively characterized class of cortical projection neurons 3, 4 . A master transcription factor-forebrain expressed zinc finger 2 (Fezf2)-has been identified that is necessary for the fate specification of CSMN [5] [6] [7] . In the absence of Fezf2, CSMN fail to generate. In agreement, CSMN-specific genes are not expressed in layer Vb of the Fezf2 −/− mutant cortex, a deficiency accompanied by changes in dendritic morphology and a lack of axonal projections to the spinal cord [5] [6] [7] .
Conversely, Fezf2 alone can cell-autonomously instruct the acquisition of CSMN-specific features when expressed in diverse, permissive cellular contexts in vivo. Ectopic overexpression of Fezf2 in progenitors and postmitotic neurons of different lineages is sufficient to induce the generation of neurons that express multiple CSMN genes and extend axons to subcerebral targets 5, [8] [9] [10] . Beyond acquisition of lineage-specific CSMN features, neurons expressing Fezf2 also acquire necessary cortical pan-projection neuron features. They become glutamatergic and develop distinctive pyramidal morphology 8 . These data indicate that Fezf2 is sufficient to instruct the acquisition of multiple aspects of CSMN identity.
Here we demonstrate that Fezf2 is a selector gene for an individual class of neurons of the neocortex: corticospinal motor neurons. We found that activation and repression of large batteries of genes necessary to orchestrate the acquisition of CSMN defining traits was directly co-regulated downstream of Fezf2. Fezf2 was sufficient to induce vesicular glutamate transporter 1 (Vglut1) and to repress glutamate decarboxylase 1 (Gad1) expression to instruct the acquisition of glutamatergic identity. In addition, we uncovered a new role for EphB1 as a functionally relevant effector of Fezf2, required to execute the ipsilateral extension of the corticospinal tract through the ventral forebrain. Our data indicate a direct role for Fezf2 as a selector gene that coordinates the expression of pan-neuronal and class-specific genes required for the developmental acquisition of CSMN identity. a r t I C l e S
RESULTS

Fezf2 induces signature genes of corticospinal neurons
To understand the molecular logic underlying the acquisition of CSMN traits upon Fezf2 expression, we compared the in vivo gene expression of FACS-purified cortical progenitors that ectopically expressed Fezf2 to control progenitors. We used in utero electroporation to deliver Fezf2 GFP or Ctrl GFP (see Online Methods) expression vectors to neocortical progenitors at embryonic day (E) 14.5, when they primarily generate callosal projection neurons (CPN) of the upper layers (Supplementary Fig. 1a) . Overexpression of Fezf2 in these progenitors is sufficient to instruct a fate switch resulting in the generation of CSMN and other subtypes of corticofugal projection neurons 5, 7, 11 . Fezf2 GFP -and Ctrl GFP -electroporated progenitors were FACS-purified 24 and 48 h after surgery ( Supplementary Fig. 1b,c) and acutely profiled by microarrays.
A large set of genes was induced by Fezf2 as early as 24 h (263 genes; P < 0.001, fold change > 1.5), while others were induced not earlier than 48 h (441 genes; P < 0.001, fold change > 1.5) after electroporation. In addition, we identified a smaller set of genes repressed by Fezf2 (90 genes at 24 h; 89 genes at 48 h; P < 0.001, fold change > 1.5) (Supplementary Table 1) .
To investigate whether genes induced by Fezf2 mark developing CSMN, we performed in situ hybridization for selected candidates (Supplementary Table 1 ) at multiple stages of embryonic and postnatal development of the cerebral cortex (E15.5, E18.5, postnatal day (P) 3, P7 and P14; Fig. 1 and Supplementary Fig. 2 ). Remarkably, we identified a series of Fezf2 target genes (for example, Ldb2, Adcyap1, Akap12, Ephb1, Rgs16, Rgs8, Acvr1c, Pappa2, Kif26a) that labeled developing CSMN (and related subcerebral projection neurons, ScPN) in the early cortical plate ( Fig. 1 and Supplementary Fig. 2 ), whereas other targets (for example, Kif26a, Tshz2, Tmem163, Cntn6, C1ql3, Parm1) were specific to later stages of CSMN development ( Fig. 1 and Supplementary Fig. 2 ).
To precisely define the neuron subtypespecific expression of the identified transcripts, we performed colocalization analyses of all the selected Fezf2-induced genes with CTIP2, a wellestablished marker of CSMN and other ScPN 3 . As expected, all genes tested showed various degrees of colocalization with CTIP2 ( Fig. 2 and Supplementary Fig. 3a) . Among the embryonic CSMN marker genes, Adcyap1 showed restricted expression both in cortical progenitors at E13.5, the peak of CSMN neurogenesis, and subsequently in developing layer V (Fig. 2a) . Adcyap1 expression molecularly defined a subpopulation within the broader group of CTIP2 + neurons (Fig. 2b) . At postnatal stages, Kif26a expression similarly defined a subset of CTIP2 + neurons (Fig. 2c) , whereas Tmem163 labeled most of the CTIP2 + population in the cortex (Fig. 2d) .
To investigate whether Fezf2 is required for the expression of the identified target genes, we performed in situ hybridization for 13 genes on Fezf2 −/− cortex. We found that, in the absence of Fezf2, the expression of all genes tested was abrogated or decreased in layer Vb. Notably, the effect of Fezf2 loss on expression was selective for layer Vb, as these genes were maintained in other layers Figure 1 Fezf2 overexpression in cortical progenitors induces genes that label corticospinal motor neurons. Left, in situ hybridizations on coronal sections of the cerebral cortex at different embryonic (E15.5, E17.5 and E18.5) and postnatal stages (P3, P7 and P14) (insets enlarged from boxed areas). Right, expression levels (normalized microarray intensity; see Online Methods) for each selected gene in Ctrl GFP (blue) and Fezf2 GFP (red) in utero electroporated cortical progenitors that were collected at 24 h (n = 3 litters per condition) and 48 h (n = 4 litters per condition). Vertical axes are normalized intensities (arbitrary units). Error bars indicate s.e.m. LV, lateral ventricle; Str, striatum. Scale bars, 100 µm; 50 µm in insets. Source data are shown in Supplementary Table 1. npg a r t I C l e S (Supplementary Fig. 3b ). These data indicate that Fezf2 induces numerous early and late CSMN genes and that Fezf2 is required for the expression of its targets in layer Vb.
Fezf2 induces a transcriptome shift toward nascent CSMN To examine how early during development Fezf2 governs expression of CSMN genes, we interrogated our target gene list against available RNA sequencing data from E14.5 cortical plate, subventricular zone (SVZ) and ventricular zone (VZ) 12 . At E14.5 the cortical plate is mostly populated by early postmitotic corticofugal neurons (including nascent CSMN). In contrast, the SVZ and the intermediate zone (SVZ/IZ) primarily contain basal progenitors of upper layer CPN [13] [14] [15] and early postmitotic upper layer CPN 16 . Finally, the VZ is mostly populated by apical progenitors generating upper layer CPN 15 . We found that Fezf2 overexpression upregulated 186 genes enriched in the cortical plate versus SVZ/IZ and VZ ( Supplementary Fig. 4 and Supplementary Table 2) .
We next compared the Fezf2-induced genes to the available transcriptome of purified CSMN 3 . Strikingly, within 48 h, Fezf2 overexpression had already induced 30 genes known to be restricted to early postnatal CSMN (Supplementary Table 3 ).
Next we investigated whether Fezf2 repressed genes of alternative neuronal fates. We found that 73 genes repressed by Fezf2 (at both 24 and 48 h) were preferentially expressed in the E14.5 VZ and SVZ/IZ, which mainly contain progenitors of upper layer projection neurons ( Supplementary Fig. 5 and Supplementary Table 2 ). In agreement, comparative analysis with genes known to be expressed in purified CPN 17 showed that Fezf2 repressed 17 genes including Cux1, Zfhx4, Fzd1 and Btbd11. These included early markers of the CPN lineage, such as Cux2, shown to mark progenitors fated to an upper layer identity 15 . The data indicate that, when expressed in progenitors of upper layer CPN, Fezf2 induces a battery of transcripts that collectively define developing CSMN and represses genes of developing CPN.
Fezf2 associates with the proximal promoters of CSMN genes
To elucidate the strategy used by Fezf2 to instruct CSMN identity, we performed a genome-wide DNA binding analysis for Fezf2 in cortical progenitors, using chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 18 in combination with RNA-seq. Cortical neural progenitors were isolated at E14.5 and expanded in vitro for one passage as neurospheres. The neurospheres were infected with retroviruses encoding epitope-tagged Fezf2 (3xFlag-Fezf2) or control (3xFlag) and harvested 48 h after infection for anti-Flag ChIP (Supplementary Fig. 6a ). The 3xFlag-tagged Fezf2 was confirmed to be functional by in utero electroporation ( Supplementary Fig. 6b-e) .
Two replicates of the ChIP-seq data were analyzed independently using the GEM (genome-wide event finding and motif discovery) integrative computational method 19 . In the two replicates, GEM analysis predicted 15,665 binding events with significant enrichment in 3xFlag-Fezf2 over control (P < 10 −3 ; Supplementary Table 4 ). Of these, 81.8% fell within 5 kb of the transcription start site (TSS) of 12,860 annotated genes ( Fig. 3a and Supplementary  Table 4) . Genes bound by Fezf2 contained over 63% of known CSMN genes 3 (Supplementary Table 4) , including those expressed at early (Fig. 3b-c) , middle ( Fig. 3d) and late stages of CSMN maturation ( Fig. 3e-i) .
To assess the relationship between DNA binding and transcriptional regulation by Fezf2, we performed comparative RNA-seq analysis of 3xFlag-Fezf2 and 3xFlag neurospheres 48 h after infection (Supplementary Fig. 6a ). We identified 1,295 transcripts differentially expressed upon Fezf2 induction, including 747 upregulated and 548 downregulated genes (false discovery rate = 10%; Supplementary Table 5 Fig. 7a and Supplementary Table 5 ). In contrast, 155 genes downregulated by Fezf2 were preferentially expressed in VZ and SVZ/IZ and were enriched for cell-cycle genes ( Supplementary Fig. 7b and Supplementary Table 5) . Genes upregulated by Fezf2 in neurospheres npg a r t I C l e S also showed enrichment for CSMN versus CPN signature genes by gene score enrichment analysis (GSEA) (Fig. 3j and  Supplementary Table 4) . Collectively, this indicates that Fezf2 induces similar transcriptional changes in isolated cortical progenitors to the ones observed in vivo.
We found that 64.1% of the genes induced and 77.4% of those downregulated by Fezf2 in cortical neurospheres were promoter-bound ( Supplementary Fig. 8a,b) . Similar percentages were observed when using transcripts regulated by Fezf2 in vivo ( Supplementary Fig. 8c,d ). These represent a significantly greater proportion of genes than expected by chance (Online Methods, Supplementary Fig. 8c -e and Supplementary Table 6 ; chi-squared test, all P < 0.000005). GSEA analysis of genes that were both transcriptionally regulated and promoter-bound by Fezf2, against sets of CSMN and CPN signature genes (Supplementary Table 4 ), showed that only CSMN signature genes were significantly enriched in the Fezf2-upregulated targets (Fig. 3j) .
GEM motif-finding analysis identified a GC-rich sequence (CGCCGC) that is enriched at Fezf2-bound sites ( Supplementary  Fig. 9a ). Since Fezf2-bound promoters are slightly more GC-rich than unbound ones (64.4% versus 49.6% GC content; Supplementary Fig. 9b ), it is difficult to conclude whether Fezf2 directly binds to this motif. Nevertheless, this sequence was present in 42.9% of Fezf2-bound TSSs compared to 11.2% of unbound TSSs. In addition, electrophoretic mobility shift assay on selected target promoters containing this sequence (namely, Ascl1 and Ephb1) showed binding by Fezf2 ( Supplementary Fig. 9c,d ). Previously reported consensus sequences predicted either by SELEX (systematic evolution of ligands by exponential enrichment) in zebrafish 20 or using protein-DNA arrays in the human protein-DNA interactome (hPDI) 21 were present in 15.4% for hPDI and 3.9% for SELEX of all Fezf2-bound sites, respectively, while the GEM-defined motif was present in 48.6% of these sites ( Supplementary Fig. 9b ).
Together, these data indicate that Fezf2 activates and represses a broad program of neuron subtype-specific genes by binding to proximal promoters.
Fezf2 selects glutamatergic and represses GABAergic fate
To functionally test whether genes regulated by Fezf2 control the acquisition of CSMN traits, we concentrated on two defining features of CSMN: glutamatergic identity and axonal extension to the spinal cord. Glutamate signaling is a terminal, necessary feature of all cortical projection neurons. It is unknown whether fate-specifying transcription factors for cortical neuron classes also instruct the establishment of this pan-neuronal trait. We found that Fezf2 bound to the promoter of Vglut1, the vesicular glutamate transporter used by most cortical projection neurons, including CSMN 22 , and was sufficient to induce its expression in cortical neurospheres (Fig. 4a,b) . The binding appeared specific, as Vglut2 (Slc17a6), used only by glutamatergic neurons in cortical layer IV and outside of the cortex 22 , was neither bound nor transcriptionally regulated. Concomitantly, Fezf2 bound to the promoter of Gad1 (Gad67), necessary for establishment of GABAergic identity, but repressed its expression (Fig. 4a,b) . To test the extent to which Fezf2 can instruct neurotransmitter choice, we established doxycycline-inducible Fezf2-IRES-GFP (iFIG) and control GFP (iGFP) mouse embryonic stem cell lines and induced and late (Pcp4, Opn3, Diap3, S100a10 and Cdh22; e-i) CSMN genes. In situ hybridizations are shown for Crim1 (P21), Pcp4 (P21), Opn3 (P21), S100a10 (P21), Diap3 (P14) and Cdh22 (P21). Immunohistochemistry results are shown for SOX5 (E18.5) and CTIP2 (P1). Scale bars, 100 µm (b-i). (j) GSEA for CSMN and CPN signature gene sets. Signature gene sets (in red) and the corresponding subsets bound by Fezf2 (in blue) were assessed for enrichment in Fezf2-overexpressing neurospheres. The zero cross area represents genes where the Cuffdiff2 test statistic is equal to 0 and no appropriate rank information is available. The color scales used for the rank density represent kernel density estimate of gene rank positions (white represents 0; red and blue represent maximum density). Both CSMN signature genes and the subset bound by Fezf2 were significantly enriched in Fezf2-overexpressing neurospheres. Neither set of CPN signature genes showed significant enrichment. Source data are shown in Supplementary Table 4. npg a r t I C l e S neural differentiation using the serum-free embryoid body quick (SFEBq) protocol 23 ( Fig. 4c,d and Supplementary Fig. 10 ). GFP + cells were FACS-sorted and profiled by RNA-seq. Confirming our results in primary cortical progenitors, Fezf2 overexpression induced Vglut1, had no effect on Vglut2 and inhibited the expression of Gad1 (Fig. 4e) . Together, these data indicate that Fezf2 is sufficient to select the appropriate effector genes to establish the neurotransmitter identity of CSMN, while repressing an alternative GABAergic fate.
Fezf2 directly controls expression of Ephb1 in CSMN
Axonal connectivity to the spinal cord is a defining class-specific trait of CSMN. Directed axonal extension begins soon after CSMN fate specification and is strictly guided under the control of multiple axon guidance molecules (reviewed in ref. 24) . Gene Ontology analysis of the Fezf2-induced genes showed a significant enrichment in axon guidance molecules (P = 0.026 at 24 h; Supplementary Fig. 11a ). Fezf2 associated with the proximal promoters of 78% of these genes (Supplementary Table 4) , including neuropilin 2 (Nrp2) and Robo1, which are known to affect the extension and guidance of the corticospinal tract. Among these, we selected for further analysis Ephb1 (Fig. 1) , encoding a tyrosine kinase receptor that mediates axon guidance and is critical for midline repulsion decisions [25] [26] [27] and whose function in CSMN remains unknown.
We first profiled Ephb1 expression in the developing cortex by in situ hybridization. Ephb1 mRNA peaked in the cortical plate at E15.5, when CSMN axonal extension begins. Ephb1 expression remained restricted to developing layer V, and at lower levels in layer VI, until approximately E18.5 (Fig. 5a) . Postnatally, Ephb1 levels drastically decreased, and by P14 expression was weak and detectable only in layer VI (Fig. 5a ) in both TBR1 + projection neurons 28 and APC + oligodendrocytes (Fig. 5b) 29 .
To define the neuron subtype-specific expression of Ephb1 within layer V, we used β-galactosidase (β-gal) as a proxy for endogenous Ephb1 expression in mice in which a lacZ cassette has been knocked into the Ephb1 locus (see Online Methods; Supplementary Fig. 11b ). Virtually all of the β-gal + neurons were CTIP2 + and negative for SATB2, a marker for CPN 30, 31 (Fig. 5c) . In addition, we retrogradely labeled ScPN and CPN by injecting FluoroGold into the pons and the contralateral hemisphere, respectively. We found that β-gal was expressed in FluoroGold-labeled ScPN and excluded from CPN labeled from contralateral cortex (Fig. 5c ). These data demonstrate that, in the developing cortex, Ephb1 is specifically expressed in neuronal subtypes that extend ipsilateral axonal projections and is excluded from neuronal subtypes that project through the cortical midline.
To investigate whether Fezf2 is required for Ephb1 expression, we performed in situ hybridization on cortical sections from Fezf2 −/− mice at E18.5. In the absence of Fezf2, Ephb1 was no longer expressed in ScPN, and expression was maintained only at very reduced levels in layer VI (Fig. 5d) . In agreement, our ChIP-seq data showed that Fezf2 associates with the proximal promoter of the Ephb1 gene, within a 310-base-pair region at the TSS ( Fig. 5d and Supplementary Fig. 9d ). Ephb1 expression was unchanged in the striatum of Fezf2 −/− mice, a region that does not endogenously express Fezf2 (Fig. 5d ). These data demonstrate that Fezf2 is required for the expression of Ephb1 in ScPN. 
(P28) were processed by immunohistochemistry for myelin basic protein to visualize myelinated axons. Mutant mice displayed clear abnormalities of major axon tracts (Fig. 6) . The internal capsule comprised smaller than wild type and partly unfasciculated axon bundles (Fig. 6a,b) . These abnormalities were accompanied by an expansion of the external capsule ( Fig. 6a,c; arrows) and the anterior commissure ( Fig. 6a,d; arrowheads) . In addition, ectopic axon bundles extended within the internal capsule toward the external capsule and continued to grow ventrally (Fig. 6a,d) .
We hypothesized that, in the absence of EphB1, the trajectories of subcerebral axons are rerouted, abnormally crossing to contralateral targets via the anterior commissure. To test whether the ectopic axon tracts were of neocortical origin, we anterogradely traced neocortical a r t I C l e S output projections with the lipophilic tracer DiI injected in the sensorimotor cortex of Ephb1 −/− and wild-type littermates at P2. DiI labeled axons were found in the corpus callosum and internal capsule in both wild-type and Ephb1 −/− mice. However, only in the mutant mice did we observe distinct DiI-labeled axons crossing at the anterior commissure and extending ventrally and rostrally (Fig. 6e) . In wildtype cortex, only neurons located in the most lateral cortical areas, the posterior perirhinal cortex, and the entorhinal cortex project contralaterally through the anterior commissure 32 . In the Ephb1 −/− mice, however, neurons located in dorsal areas projected ectopically through this commissure.
To confirm and visualize the axonal projection routes in the absence of EphB1, we used high-angular-resolution diffusion imaging (HARDI) tractography to render a three-dimensional image of major axon tracts in mutant and wild-type brains 33, 34 . We found that axon fibers in the dorsal areas of the neocortex merged with the anterior commissure in the Ephb1 −/− but not in wild-type brains (Fig. 6f) . To identify a potential source of EphB1 ligands, we performed in situ hybridization for the ephrin genes Efnb1, Efnb2 and Efnb3. We found that only Efnb3 was expressed at the ventral forebrain midline and thus might mediate EphB1-dependent repulsion of ipsilateral descending tracts (Supplementary Fig. 12 ).
Reduced corticospinal tract in Ephb1 null mutants
To determine whether the corticospinal tract is specifically affected by EphB1 loss, we used the Fezf2øPLAP (placental alkaline phosphatase) reporter line 7 to genetically trace CSMN axons in control (Ephb1 +/− ; Fezf2 PLAP/+ ) and EphB1-deficient (Ephb1 −/− ;Fezf2 PLAP/+ ) mice at P7. In control mice, PLAP-positive axons were exclusively observed extending along ipsilateral, corticofugal trajectories (Fig. 7a) . In contrast, in EphB1-deficient mice, a large proportion of PLAP-positive axons extended inappropriately to contralateral targets, crossing the midline via an enlarged anterior commissure (Fig. 7b) . Most notably, this resulted in a drastic reduction of subcerebral axons reaching the cerebral peduncle (Fig. 7b) and of corticospinal axons in the dorsal funiculus of the spinal cord (Fig. 7b) . These results demonstrate that, in the absence of EphB1, the ipsilateral axonal trajectories of the corticospinal tract are compromised and a distinct proportion of axons take contralateral, crossed routes through the anterior commissure.
It is notable that Fezf2 −/− mutants also show loss of axonal projections to the cerebral peduncle and the spinal cord (Fig. 7c and  refs. 5-7) , accompanied by an expansion of the anterior commissure ( Fig. 7c and ref. 7) . This phenotype is reminiscent of that observed in the EphB1-deficient mice ( Fig. 7b and Supplementary Fig. 13 ). Beyond connectivity, in the absence of Fezf2 the global fate specification of CSMN (molecular identity, electrophysiological properties and connectivity to the spinal cord) is abolished [5] [6] [7] . In contrast, we found that loss of EphB1 did not affect the fate specification of projection neuron classes, which showed normal expression of the canonical projection neuron subtype-specific markers CTIP2, TBR1, SATB2 and CUX1 (Supplementary Fig. 13 ). The data indicate that EphB1 is an effector molecule directly downstream of Fezf2 that executes a specific modular aspect of the global Fezf2 −/− phenotype.
DISCUSSION
Deciphering the molecular logic that orchestrates the acquisition of neuronal subtype-specific features in the mammalian cerebral cortex is fundamental to understanding how its neuronal diversity has evolved. These molecular rules are not yet defined for any subtype of cortical neuron. Here we report that acquisition of defining features of corticospinal motor neurons is at least partly achieved by co-regulated expression of batteries of CSMN effector molecules directly downstream of a single selector gene, Fezf2.
Precise control over activation and repression of transcription factors responsible for acquisition of class-specific traits in projection neurons is critical to resolve neuronal fates during cortical development. Tbr1 and Sox5 act as repressors of Fezf2 to negatively regulate the extension of the corticospinal tract and to promote connectivity to the thalamus [35] [36] [37] [38] . Similarly, reciprocal repression of Fezf2, Satb2 and Ctip2 is employed to choose subtype-specific long distance connectivity 39, 40 . These studies motivate a more global analysis of the molecular rules beyond single genes that govern the acquisition of lineage-specific traits.
We found that expression of Fezf2 in cortical progenitors fated to generate upper layer neurons resulted in both the induction of a large series of genes expressed in nascent CSMN and the repression of molecular programs of upper layer neurons. Given that this transcriptional regulation largely occurred via binding of Fezf2 to the promoters of both activated and repressed genes, the data indicate that lineage bifurcation decisions can be co-regulated by the same transcription factor from very early stages of differentiation. Our data also provide a molecular explanation for why, during development, cortical progenitors tune Fezf2 expression to the lower levels observed in late-stage cortical progenitors 5, 7, 41 . Maintenance of Fezf2 expression after the completion of neurogenesis of deep layer neurons may be molecularly incompatible with the initiation of upper layer neurogenesis.
Much work is still required to understand the nuances of how Fezf2 can act as an activator for some target genes and as a repressor a r t I C l e S for others. It is likely that factors such as post-translational modification of Fezf2, the choice of interacting cofactors and the presence of neighboring binding sites for different proteins at different loci critically contribute to these distinct transcriptional outcomes 42 .
Transcription factors endowed with properties of classic selector genes have been identified in different tissues as genes uniquely able to control 'master' molecular switches of distinct cellular fates. Elegant work in Drosophila has highlighted core properties of selector genes that clarify the logic guiding their activity. Multiple target genes are often regulated downstream of a single selector gene, and targets often include both activated and repressed genes 43 . Our evidence that Fezf2 acts as both an activator of CSMN genes and a repressor of genes for alternative fates further supports the idea that Fezf2 is a selector gene. To our knowledge, this is the first transcription factor endowed with these properties for any class of cortical neurons.
During development of CSMN, expression of lineage-specific and pan-neuronal genes alike display temporally dynamic regulation. It is intriguing that within 48 h of induction, Fezf2 is already associated with the promoters of CSMN genes whose expression is normally temporally spaced during CSMN differentiation. The data suggest that, in cortical progenitors, Fezf2 might be 'priming' the transcriptional territory of CSMN by also occupying genomic loci that are transcriptionally active in these neurons at later times. This implies that temporal resolution of gene expression over the several weeks of CSMN development likely relies on cofactors that operate by interaction with Fezf2 or work on the genomic loci that are primed by early Fezf2 binding. The fact that Fezf2 expression is maintained at all stages of CSMN differentiation in vivo [5] [6] [7] supports the view that active binding by Fezf2 to CSMN loci may be required to poise them for transcriptional regulation at later stages of differentiation.
Precedents exist for the use of early priming of genomic loci in progenitor cells to enable the execution of specific differentiation programs at later stages of development. In Caenorhabditis elegans, asymmetric distribution of gene expression in bilaterally symmetrical ASE gustatory neurons relies on early priming of the Isy-6 microRNA locus in progenitors of only the left neurons 44 . MyoD has also been shown to associate with enhancers of both early and late myogenic genes 45 .
In his first definition of selectors, Antonio García-Bellido postulated that these genes would regulate effector molecules necessary for the acquisition of specific cellular features 46 . Here we identify EphB1 as an effector molecule of Fezf2. In turn, EphB1 executes CSMN axonal repulsion from the midline in the ventral telencephalon, enabling the ipsilateral extension of the corticospinal tract. Our data are in agreement with work demonstrating a key role for EphB1 in mediating midline repulsion decisions. In the spinal cord, EphB1 instructs the ventral trajectory of motor neuron axons by mediating their repulsion from the mesenchyme of the dorsal limb 25 . Similarly, in the optic chiasm, EphB1 mediates the repulsion of retinal ganglion cell (RGC) axons from the midline 47 . Notably, in the retina the transcription factor Zic2 is also upstream of genes critical for both axonal guidance decisions (EphB1) and neurotransmitter identity (Sert) 48 .
The regulation of axon guidance molecules in different classes of cortical projection neurons has just begun to be explored 40 . Whether expression of lineage-specific axon guidance molecules is directly controlled by the same transcription factors that govern neuron subtype fate specification remains unknown. It is striking that the phenotypic abnormalities observed in the absence of EphB1 mimic the axon guidance defects observed in the Fezf2 −/− mutants, without affecting the overall fate specification of CSMN. While the possibility that expression of EphB1 in thalamus or striatum contributes to this phenotype 49 cannot be ruled out, the fact that Fezf2 is not expressed in these regions and yet Fezf2 −/− mice present similar axon guidance defects to Ephb1 mutants supports a cell-autonomous role of EphB1 in CSMN. Our data point to a direct regulation of key CSMN axon guidance receptors by the same selector gene that governs global programs of fate specification of this neuron subtype.
Not all selector genes have equal properties. Pioneering work in C. elegans has identified ones termed terminal selector genes sufficient to instruct specific neurotransmitter fates 50 . Our data indicate that Fezf2 controls the acquisition of glutamatergic identity by direct binding to the promoter of Vglut1 and other genes involved in the synthesis, transport and signaling of glutamate. This is in agreement with the fact that overexpression of Fezf2 in progenitors of GABAergic medium spiny neurons results in a switch to a glutamatergic fate in vivo 8 . In addition, like selector genes in C. elegans, Fezf2 expression is maintained in CSMN throughout life, suggesting a requirement for Fezf2 to both establish and maintain CSMN traits. In the future, conditional loss of Fezf2 in adult CSMN will test this possibility and define the extent to which Fezf2 fulfills the definition of a canonical terminal selector. An understanding of the molecular regulatory architecture that shapes the identity of CSMN and other classes of cortical neurons is fundamental to gaining insights into how neuronal diversity develops in the cerebral cortex and will furthermore inspire tools to reprogram class-specific neuronal identity in the context of neurodegenerative disease.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. GEO: raw and processed ChIP-seq data, GSE46707; RNA-seq data, GSE56446; microarray data, GSE56451. Mapped ChIPseq data can be browsed at http://genome.ucsc.edu/cgi-bin/hgTracks? db=mm9&hgtcustomText=http://nanog.csail.mit.edu/csmn/arlotta_ fezf2.csmn.tracks&position=chr9:101716317-102365165. a r t I C l e S Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html.
ONLINE METHODS
mice. Fezf2 −/− mice were generated by Hirata et al. 41 (Fezf2 GenBank accession code: AB042399). Ephb1 −/− mice (Ephb1 GenBank accession code: NM_173447) were generated by Deltagen, Inc. (Menlo Park, CA). The line was generated by targeting the Ephb1 coding region with a cassette containing a 4.5-kb homology sequence upstream of exon 8, a Lac0-SA-IRES-lacZ-WT Neo/Kan cassette and a 2.2-kb homology sequence downstream of exon 8. The insertion of the Lac0-SA-IRES-lacZ-WT Neo/Kan cassette resulted in a 100-bp deletion of genomic DNA. Sequences of PCR primers employed to genotype the Ephb1 −/− line are as follows: forward primer, ACGTGGGAGGA CTCTAATCCTCTTC; reverse primer (wild-type allele), TCTAGGTTGCTG GCTACAGGACTTG; reverse primer (Neo), GGGCCAGCTCATTCCTCCC ACTCAT. Fezf2øPLAP (Fezf2 PLAP/+ ) mice were generated by Chen et al. 7 and crossed with the Ephb1 +/− mutant line to obtain Ephb1 −/− ;Fezf2 PLAP/+ mutants. Timed-pregnant CD-1 mice were obtained from Charles River Laboratories (Wilmington, MA) for in utero electroporation. The day of the vaginal plug was designated embryonic day 0.5 (E0.5). The day of birth was designated postnatal day 0 (P0). All mice were maintained in standard housing conditions on a 12-h light/dark cycle with food and water ad libitum. No more than four adult animals were housed per cage. All mouse studies were approved by the Massachusetts General Hospital and Harvard University Institutional Animal Care and Use Committee and were performed in accordance with institutional and federal guidelines.
In utero electroporation. The Fezf2 GFP and Ctrl GFP construct and conditions for in vivo electroporation were described previously 5, 51 . The 3xFlag-Fezf2 open reading frame was cloned into the Ctrl GFP construct driven by the CAG promoter. Briefly, 800 nl of purified DNA (2 µg/µl) mixed with 0.005% fast green in sterile PBS was injected in utero into the lateral ventricle of CD1 embryos at E14.5 under ultrasound guidance (Vevo 770, VisualSonics). Five 40-V pulses of 50 ms were delivered at 1-s intervals in an appropriate orientation across the embryonic head using 1-cm-diameter platinum electrodes placed outside the uterus, using a CUY21EDIT square wave electroporator (Nepa Gene). Injected embryos were collected for FACS purification either 24 h or 48 h after electroporation.
FAcS purification. Pregnant dams were deeply anesthetized 24 h or 48 h after surgery. Their embryos were removed and sensorimotor cortex was microdissected, as previously described 52 , from the electroporated cerebral hemisphere using a fluorescence dissecting microscope to precisely visualize the labeled regions. Fezf2 GFP and Ctrl GFP electroporated cells were purified by FACS directly into RNAlater 53 and RNA was extracted as previously described 54 .
To control for biological sample variability, we processed multiple independently collected samples for both Fezf2 GFP and Ctrl GFP electroporated cells at each time point of analysis (true biological replicates) for a total of fourteen samples derived from different litters, FACS purifications and microarray hybridizations (three each of Fezf2 GFP and Ctrl GFP at 24 h and four each at 48 h). Fezf2 GFP -and Ctrl GFP -labeled cortical tissues were enzymatically digested in dissociation medium (20 mM glucose, 0.8 mM kynurenic acid, 0.05 mM APV, penicillin-streptomycin (50 U/ml and 0.05 mg/ml, respectively), 0.09 M Na 2 SO 4 , 0.03 M K 2 SO 4 and 0.014 M MgCl 2 ) containing l-cysteine HCl (0.016 µg/µl) and papain (10 unit/ml; Worthington Biochemical Corp., NJ) at 37 °C for 30 min. Papain digestion was stopped with ovomucoid (10 mg/ml) and BSA (10 mg/ml) in dissociation medium at room temperature. Progenitors were mechanically dissociated to obtain a single-cell suspension by gentle trituration in iced OptiMEM containing glucose (20 mM), kynurenic acid (0.4 mM) and APV (0.025 mM). All chemicals were purchased from Sigma, and all media were purchased from GIBCO-BRL. GFP-positive cells were purified using a BD FACS Vantage SEM DiVa cell sorter. Cells were gated on the basis of on fluorescence, forward scatter and side scatter to select the appropriate population. FACS-purified progenitors and neurons from both time points were collected and stored in RNAlater before RNA extraction 53 . microarray and analysis. Approximately 10,000 to 30,000 FACS-sorted progenitors were used for each biological replicate. RNA was extracted using the StrataPrep Total RNA Micro Kit (Stratagene), and RNA quality was assessed using a Bioanalyzer (Agilent Technologies). RNA was amplified per Affymetrix small sample protocol using two consecutive rounds of linear in vitro transcription to obtain 15-20 µg of amplified and labeled cRNA for each hybridization. Microarray hybridization was performed with an Affymetrix Mouse Genome 430 2.0 Array according to standard Affymetrix protocol 55 . For microarray experiments, 3 or 4 replicates were used at each age, which allows the identification of differential gene expression with low false discovery rates 3 .
Using the Rosetta Resolver software (Rosetta Biosoftware), data from individual microarrays were normalized with the trend function and replicates were combined. Statistical significance of gene expression differences between Fezf2 GFP and Ctrl GFP experiments was determined by pairwise comparisons at each time point using the Rosetta Resolver error modeling method 56 with P-value limit of <0.001 and fold change of >1.5. Similar results were obtained by normalizing with GCRMA in Bioconductor 57 or with the Bioconductor implementation of MAS 5.0 and performing pairwise comparisons using significance analysis of microarrays (SAM) 58 .
For comparison with RNA-seq expression data from Ayoub et al. 12 , BAM files were downloaded from NCBI (accession code GSE30765), differential expression was determined with Cuffdiff, and analysis was performed with the Cummerbund package in the R language and environment for statistical computing and graphics 59 . From a list of genes with significant differential expression between VZ, SVZ and cortical plate (P < 0.001) in at least one sample, those with significant up-or downregulation induced by Fezf2 were identified and subsequently used for cluster analysis with Jensen-Shannon divergence as the distance metric in Cummerbund.
western blot. Brains were dissected from P1 Ephb1 knockout, heterozygous and wild-type mice and lysed in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS, 1 mM EDTA, 50 mM Tris-HCl, pH 8) with proteinase inhibitors (S8830, Sigma-Aldrich). Mouse ES cells were treated with 2 µg/ml doxycycline for 48 h and harvested in RIPA buffer. After quantification by Bio-Rad protein assay (Bio-Rad), proteins were resolved in 4-12% SDS-PAGE gels and transferred to a nitrocellulose membrane. The western blot was performed using goat anti-EphB1 (M19, Santa Cruz, 1:250), rabbit anti-Fezf2/ Fezf1 (F441, IBL, 1:500), rabbit anti-β-tubulin (9F3, Cell Signaling, 1:500) and mouse anti-α-tubulin (T9026, Sigma, 1:5,000). Anti-goat, anti-rabbit and antimouse HRP-conjugated secondary antibodies (HRP-conjugated anti-rabbit IgG, Cell Signaling Technology 7074; HRP-conjugated goat anti-mouse IgG, Cell Signaling Technology 7076; HRP-conjugated anti-goat IgG, Santa Cruz sc-2020, all at 1:5,000), followed by ECL (Amersham), were used to visualize proteins of interest on the membrane.
Retrograde and anterograde labeling. Pups were anesthetized by hypothermia at P2 and injected with FluoroGold (for retrograde labeling) in the contralateral cortex or the pons, or with DiI (for anterograde labeling) in the motor cortex as previously described 17, 60 . The site of DiI injection was identified by ultrasound guidance. Pups were returned to the care of their mother and deeply anesthetized at P4 and P7 in the retrograde tracer studies, and at P4 for the anterograde tracer study, before perfusion and collection of the brain for immunocytochemistry.
High-angular-resolution diffusion imaging (HARdI).
Four-week-old (P28) wild-type and Ephb1 −/− littermates were perfused with saline followed by 4% paraformaldehyde, postfixed for 24 h, and subsequently fixed for an additional week in 4% paraformaldehyde solution containing 1 mM gadolinium (Gd-DTPA). For image acquisition, the brains were placed in Fomblin. Brains were scanned on a 4.7-T Bruker Biospec MR system. The pulse sequence used for image acquisition was a 3D diffusion-weighted spin-echo echo-planar imaging sequence, time repetition (TR)/time echo (TE) 1,000/45.47 ms, with an imaging matrix of 96 × 96 × 128 pixels. Spatial resolution was 125 × 125 × 125 µm. Sixty diffusion-weighted measurements (b = 4,000 s/mm 2 ) and one nondiffusion-weighted measurement (b = 0) were acquired with δ = 12.0 ms, ∆ = 24.2 ms. Total acquisition time was approximately 2 h for each imaging session. The HARDI method was used to reconstruct the orientation distribution function in each voxel and resulting tractography pathways were reconstructed using a streamline algorithm for diffusion tractography 33, 61 . Diffusion Toolkit and TrackVis (http://trackvis.org/) were used to reconstruct and visualize axonal pathways. Trajectories were propagated by consistently pursuing the npg orientation vector of least curvature, and tracking was terminated when the angle between two consecutive orientation vectors was greater than the given threshold of 45° for each specimen. Brain mask volumes created by MRIcro (http://www.mccauslandcenter.sc.edu/mricro/mricro/mricro.html) were used to terminate tractography structures instead of the FA (fractional anisotropy) threshold as previously reported 61, 62 . Commissural pathways were isolated as fibers passing through the manually drawn region of interest that included the entire anterior commissure at the midline, ensuring that other fiber pathways were not contributing, as previously described 61 .
Immunocytochemistry, PlAP staining and in situ hybridization. Brains for immunocytochemistry were processed as previously described 55, 63 . Primary antibodies and dilutions used were as follows: rabbit anti-TBR1 antibody, 1:2,500 (gift from R. Hevner); rat anti-CTIP2 antibody, 1:1,000 (Abcam ab18465); rabbit anti-GFP, 1:500 (Invitrogen A11122); chicken anti-β-galactosidase, 1:500 (ICL lab CGAL-45A); mouse anti-SATB2, 1:50 (Abcam ab51502); rat anti-MBP, 1:500 (Millipore MAB386); and rabbit anti-CUX1, 1:100 (Santa Cruz CDP M-222). Goat anti-rabbit IgG Alexa Fluor 488, 546 and 647 (Life Technologies A11070, A-11071, A21246), goat anti-chicken IgG Alexa Fluor 488, 546, 647 (Life Technologies A11039, A11040, A21449), goat anti-rat 488, 546, 647 (Life Technologies A11006, A11081, A21247), goat anti-mouse IgG Alexa Fluor 488, 546, 647 (Life Technologies A11017, A11018, A21237) secondary antibodies were diluted 1:750. PLAP activity was detected with alkaline phosphatase staining buffer (0.1 mg/ml 5-bromo-4-chloro-3-indolyl phosphate; 1 mg/ml nitro blue tetrazolium in 100 mM Tris-HCl, pH 9.5; and 100 mM NaCl) as previously described 7 . In situ hybridization and combined in situ hybridization with immunohistochemistry were performed following published methods and using 40-µm-thick sections cut on a vibrating microtome and mounted on Superfrost slides (Fisher) 64 . Riboprobes were generated as previously described 54 . The cDNA template clone for Ldb2 was provided by J. Macklis; all other riboprobes were generated from cDNA template clones using the primers listed below. Tissue sections were imaged using a Nikon 90i fluorescence microscope equipped with a Retiga Exi camera (Q-Imaging) and analyzed with Volocity image analysis software v4.0.1 (Improvision). All primary data from immunohistochemistry and in situ hybridization experiments were repeated at least three times and analyzed by one investigator, then confirmed by a second, independent investigator who was blinded to genotype and experimental conditions.
In situ hybridization riboprobe templates. cDNA templates for riboprobes were obtained by RT-PCR with the following primer pairs (listed as gene name, forward primer, reverse primer, product length in base pairs):
Acvr1c, AGGACTTGCCTCGAAAGTGA, GAAAGCAGAAGCGGACA TTC, 610.
Adcyap1, AATGACTTGGGGAATTGCTG, GCATGAACAGCACTGGA GAA, 542.
Akap12, GTTGGGACCTTGAGACCAAA, TGGCACACTCATCTGTCCAT, 691.
C1ql3, AGTGTGGTCCTTCACCTGGA, CAAGAACCAAAGCTGACACG, 507.
Cntn6, GTATCTGTCCGAGAAGGTCA, GTGGACCTTGGACACTTCTA, 238.
Ephb1, CACATCCATCTCCCTTTGCT, TCCAGAAACCCTTTCCCTCT, 618.
Efnb1, ACAAGCCACACCAGGAAATC, TGGGGGCAGTAGTTGTTCTC, 640.
Efnb2, ACCACACAGCTATGCAGCAG, CGAACTCCACGTCTTCTGGT, 675.
Efnb3, GCAGTGTGGACATGATGGAC, GCACACTAAAGAGCGGGAAG, 675.
Kif26a, TCCTCAGCTCCAGACTCCAT, GCGACAGTCTTTCCATCTCC, 851.
Pappa2, CCATTGTTCCACAAATGCTG, CTCGCTCCACATGTTGCTTA, 900.
Parm1, TGCACTGACCAAGCCAGATA, ACAAACAGCAAGGCAGTGAA, 700.
Rgs16, AAAAGGCTGTGTGTGTGGAAC, CTATCACTTCTGAGTCTT ACCG, 752.
Rgs8, TGAGGTCATGTTTGGGTTCA, CAGGCTCTACGGACTTCTGG, 741.
Tmem163, AGGGTCTCTGCTTGACAGGA, CCCTACATGTTGGCACA CAC, 650.
Tshz2, GGCGAAGAGGACACAGACTC, AAGGAGCGCTGTCGATAAAA, 710.
Tmem117, AACTATGCCACAACGGTGCT, TTGTAGACAGTGGGCTG TGC, 754.
EMSA was performed using the Odyssey EMSA Kit (LI-COR Biosciences, USA), following the manufacturer's protocols. Briefly, 100 nM IRDye endlabeled probe was incubated with 0, 10 or 20 µg GST-tFezf2 at room temperature for 30 min in 20 µl reaction buffer (1× binding buffer, 0.2 mM DTT, 0.25% Tween 20, 0.05 µg/µl poly(dI.dC) and 5 mM MgCl 2 ). The reactions were resolved on 4-20% Mini-PROTEAN TBE precast gel (Bio-Rad) and visualized by the Odyssey CLx infrared imaging system (LI-COR Bioscience, USA).
Statistics. Bar and line graphs represent mean values of all replicates and error bars represent s.e.m. except for RNA-seq results, in which the error bars represent 95% confidence intervals for the Cuffdiff2 model expression estimate. Animals were assigned to groups on the basis of genotype. Age-matched littermates were used as controls in all experiments. No randomization was used. For all animal experiments, data distribution was assumed to be normal, but this was not formally tested. For ISH and immunofluorescence studies, data collection and analysis were performed blinded to the conditions of the experiment. No animals were excluded from analyses. Except for RNA-seq and ChIP-seq sample sizes (explained above), no statistical methods were used to predetermine sample sizes. Our sample sizes are similar to those reported in previous publications 3 .
A Supplementary methods checklist is available.
